A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06113302
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 920
- Registration Number
- NCT06109870
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Texas at Austin, Austin, Texas, United States
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06108232
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06105554
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06085729
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 240
- Registration Number
- NCT06085716
- Locations
- 🇺🇸
MD Anderson Cancer Centerr, Houston, Texas, United States
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06087263
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT06085638
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT06085664
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 224
- Registration Number
- NCT06085625
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath